These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 20055425)
1. Heat shock protein 90: inhibitors in clinical trials. Biamonte MA; Van de Water R; Arndt JW; Scannevin RH; Perret D; Lee WC J Med Chem; 2010 Jan; 53(1):3-17. PubMed ID: 20055425 [No Abstract] [Full Text] [Related]
2. Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse xenograft model. Zapf CW; Bloom JD; McBean JL; Dushin RG; Golas JM; Liu H; Lucas J; Boschelli F; Vogan E; Levin JI Bioorg Med Chem Lett; 2011 Jun; 21(12):3627-31. PubMed ID: 21605975 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites. Lee K; Ryu JS; Jin Y; Kim W; Kaur N; Chung SJ; Jeon YJ; Park JT; Bang JS; Lee HS; Kim TY; Lee JJ; Hong YS Org Biomol Chem; 2008 Jan; 6(2):340-8. PubMed ID: 18175003 [TBL] [Abstract][Full Text] [Related]
5. Purine-scaffold Hsp90 inhibitors. Chiosis G; Tao H IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299 [TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of macbecin as an Hsp90 inhibitor. Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975 [TBL] [Abstract][Full Text] [Related]
7. Structure-based and in silico design of Hsp90 inhibitors. Sgobba M; Rastelli G ChemMedChem; 2009 Sep; 4(9):1399-409. PubMed ID: 19685544 [TBL] [Abstract][Full Text] [Related]
8. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors. Zhang MQ; Gaisser S; Nur-E-Alam M; Sheehan LS; Vousden WA; Gaitatzis N; Peck G; Coates NJ; Moss SJ; Radzom M; Foster TA; Sheridan RM; Gregory MA; Roe SM; Prodromou C; Pearl L; Boyd SM; Wilkinson B; Martin CJ J Med Chem; 2008 Sep; 51(18):5494-7. PubMed ID: 18800759 [TBL] [Abstract][Full Text] [Related]
9. Total synthesis of resorcinol amide Hsp90 inhibitor AT13387. Patel BH; Barrett AG J Org Chem; 2012 Dec; 77(24):11296-301. PubMed ID: 23186098 [TBL] [Abstract][Full Text] [Related]
10. Total synthesis of herbimycin A. Canova S; Bellosta V; Bigot A; Mailliet P; Mignani S; Cossy J Org Lett; 2007 Jan; 9(1):145-8. PubMed ID: 17192106 [TBL] [Abstract][Full Text] [Related]
11. Potent triazolothione inhibitor of heat-shock protein-90. Feldman RI; Mintzer B; Zhu D; Wu JM; Biroc SL; Yuan S; Emayan K; Chang Z; Chen D; Arnaiz DO; Bryant J; Ge XS; Whitlow M; Adler M; Polokoff MA; Li WW; Ferrer M; Sato T; Gu JM; Shen J; Tseng JL; Dinter H; Buckman B Chem Biol Drug Des; 2009 Jul; 74(1):43-50. PubMed ID: 19519743 [TBL] [Abstract][Full Text] [Related]
12. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin. McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137 [TBL] [Abstract][Full Text] [Related]
13. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives. Kim T; Keum G; Pae AN Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970 [TBL] [Abstract][Full Text] [Related]
14. Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures. Gulla A; Kazlauskas E; Liang H; Strupas K; Petrauskas V; Matulis D; Eshleman JR Pancreas; 2021 Apr; 50(4):625-632. PubMed ID: 33939678 [TBL] [Abstract][Full Text] [Related]
15. HSP-90 inhibitors promise to complement cancer therapies. Vastag B Nat Biotechnol; 2006 Nov; 24(11):1307. PubMed ID: 17093460 [No Abstract] [Full Text] [Related]
16. Potent cytotoxic C-11 modified geldanamycin analogues. Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528 [TBL] [Abstract][Full Text] [Related]
17. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Gao Z; Garcia-Echeverria C; Jensen MR Curr Opin Drug Discov Devel; 2010 Mar; 13(2):193-202. PubMed ID: 20205053 [TBL] [Abstract][Full Text] [Related]
18. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors. Wang Y; Koay YC; McAlpine SR Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436 [TBL] [Abstract][Full Text] [Related]
19. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003 [TBL] [Abstract][Full Text] [Related]
20. Rational design and synthesis of ansa-adenosines as potential antitumor agents. Muranaka K; Ichikawa S; Matsuda A Nucleic Acids Symp Ser (Oxf); 2009; (53):5-6. PubMed ID: 19749232 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]